All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 25, 2021
Home » Blogs » BioWorld Perspectives » A little irony here? FDA’s technical difficulties on social media webinar send folks a’Twitter’

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Oncology

A little irony here? FDA’s technical difficulties on social media webinar send folks a’Twitter’

July 10, 2014
By Marie Powers
No Comments

webinarpicFor more than five years, the FDA was criticized for failing to provide clear guidance on how drug developers could use social media without running afoul of its marketing restrictions. Last month, the agency finally came through with two crucial draft guidances.

A webinar Thursday afternoon aimed at providing more color around the social media regulatory framework could only be described as an #EPICFAIL.

The webinar, for which registration reportedly closed early due to overwhelming demand, suffered problems from the get-go, with many registrants unable to log in at all. Almost immediately, slides started crashing, prompting the agency to pause the presentation for several minutes and try to re-sync its PowerPoint. That didn’t work, so presenters plowed ahead in audio-only format.

By the time the final presenter, Julie Chronis, began to speak, the slides were back up but the audio was intermittent and unintelligible – similar, some would say, to the FDA’s message on social media as a whole.

A few minutes into Chronis’ presentation, the FDA’s slides froze again, leaving those who actually gained access to the presentation with nothing but sound bites.

In a bit of irony, BioWorld and other industry veterans took to Twitter to express their frustration, such as these responses to our live tweets:

@BioWorld Are you still seeing a blank screen, too?

@BioWorld seems to be tweeting. @US_FDA: What's going on?

@BioWorld @US_FDA this is slightly frustrating

@BioWorld Same here. Reloading crashed the browser. Suppressing bitter/irony commentary.

@BioWorld same problem. Was logged in waiting for event. Now crashed

@BioWorld And, judging by ongoing tweets, it's already started

@BioWorld this may be why they prerecorded their ANDA webinars.

@BioWorld We are seeing a white screen here in Austin also....

You get the picture, even if @US_FDA did not.

Less than 15 minutes into the webinar, we tweeted:

#FDA_socialmedia slides crashed; pausing to allow more registered attendees to jump on

Access was never resolved, prompting this:

@US_FDA losing even more credibility on social media with massive technical difficulties for #FDA_socialmedia webinar. Still paused.

That observation was quickly picked up, in many cases with additional editorial comment.

While you could argue that posting on Twitter, Instagram or Facebook is not the same as hosting a webinar, all involve technology aimed at communicating, clearly and concisely, to a specific audience. Though the FDA is bent on regulating the messages that drugmakers send to potential patients, even 140 characters at a time, the agency could not even muster a single, articulate presentation on that very topic.

And it’s not as though preparing for this event took the agency by surprise. Even in its advisory for the webinar, the agency acknowledged that technology “is continually changing,” and “in today’s world, a tremendous amount of information exchange occurs on the web and through social media.”

FDA, heal thyself.

In the end, Thomas Abrams, director of the FDA’s Office of Prescription Drug Promotion, apologized for the massive technical problems and promised to post slides from the webinar. But it goes without saying that the agency isn’t likely to provide the same leniency to drugmakers.

The final irony? The FDA is a major user of social media in its own right. The agency knows how to do this, when it chooses. Less than an hour after finishing the botched social media webinar, the agency tweeted, @FDA_Drug_Info Join us for a webinar, "Form 356h, Update to Field 29," on July 16: go.usa.gov/Xygk.

Here’s our take:

#FDA_socialmedia webinar a complete disaster. Audio now gone, slides frozen. Are you listening, @US_FDA?

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Seniors with wooden puzzle

    Cassava’s simufilam improves AD patients’ cognition, behavior

    BioWorld
    When Cassava Sciences Inc.’s president and CEO, Remi Barbier, opened up the interim analysis of the company’s open-label study for Alzheimer’s disease candidate...
  • Vaxart COVID-19 vaccine tablets

    Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine

    BioWorld
    Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to...
  • IPO money

    Lucira Health launches $153M IPO

    BioWorld MedTech
    Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 25.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing